On January 2, 2020 ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that Jacob Chacko, MD, the Company’s Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference (Press release, ORIC Pharmaceuticals, JAN 2, 2020, View Source [SID1234552672]). Dr. Chacko’s presentation will take place on Tuesday, January 14, 2020, at 9:30 a.m. PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 2, 2020 Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, reported that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson (Press release, Pulmatrix, JAN 2, 2020, View Source;johnson-300980456.html [SID1234552671]). Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Pulmatrix’s iSPERSE platform has the ability to enhance the safety and efficacy profile of promising drug candidates," said Ted Raad, Chief Executive Officer of Pulmatrix. "We applied the iSPERSE technology to RV1162/PUR1800, the lead in-licensed inhibitor and helped unlock its clinical potential by improving the product’s profile from the original formulation. In 2020, we anticipate clinical data from the first of these inhibitors in a disease area with significant unmet medical need. We look forward to collaborating with the Lung Cancer Initiative at Johnson & Johnson as we advance this important program. Additionally, in 2020, we anticipate data from our phase 2 Pulmazole program and we plan to introduce new proprietary, wholly owned iSPERSE enabled 505(b)(2) assets to our pipeline."

Under the terms of the agreement, the Lung Cancer Initiative will pay a $7.2 million upfront payment and an additional $2 million milestone payment upon completion of the ongoing Phase 1b study of RV1162/PUR1800 in stable COPD patients, on-track for year-end 2020. If the Lung Cancer Initiative exercises the option on RV1162/PUR1800 and the portfolio of these kinase inhibitors, Pulmatrix is eligible for up to $91M in additional development and commercial milestones, as well as royalty payments.

On January 2, 2020 Global health service company Cigna (NYSE: CI) reported that David Cordani, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 in San Francisco, CA (Press release, Cigna , JAN 2, 2020, View Source [SID1234552670]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cigna’s presentation is expected to begin at approximately 10:00 a.m. PST. Investors, analysts, and the general public are invited to listen to the presentation free over the Internet via webcast by visiting View Source and clicking on About Cigna, then Investor Relations, then the Investor Events link.

To listen to this presentation live on the Internet, visit View Source at least 15 minutes prior to the presentation (to download and install any necessary audio software).

On January 2, 2020 Boston Scientific Corporation (NYSE: BSX) reported that it will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California (Press release, Boston Scientific, JAN 2, 2020, View Source [SID1234552669]). Mike Mahoney, chairman and chief executive officer, will present at approximately 8:00 a.m. PST / 11:00 a.m. EST. At 8:30 a.m. PST / 11:30 a.m. EST, Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Ian Meredith, MD, executive vice president and global chief medical officer, and Susie Lisa, vice president, Investor Relations, in a question-and-answer session with the host analyst and audience members.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Friday, January 24, 2020 Boston Scientific will host and webcast an investor update at the 2020 North American Neuromodulation Society (NANS 2020), beginning at 7:00 a.m. PST / 10:00 a.m. EST. The event will be hosted by Maulik Nanavaty, senior vice president and president, Neuromodulation and will provide a business update and answer questions from investors about the Boston Scientific Neuromodulation portfolio.

On Wednesday, February 5, 2020 Boston Scientific will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2019. The call will begin at 8:00 a.m. EST, hosted by Mike Mahoney and Dan Brennan. The company will issue a news release announcing financial results for the fourth quarter on Wednesday, February 5, 2020, prior to the conference call.

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.comView Source The replay will be available beginning approximately one hour following the completion of each event.

On January 2, 2020 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, reported that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13th at 4:00 p.m. PST/ 7:00 p.m. EST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will provide a corporate update at the conference (Press release, Mirati, JAN 2, 2020, View Source [SID1234552668]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and made available through the "Investors" section of www.mirati.com, and replays will be made available for 90 days following the event.